DIDANOSINE

US Previously Marketed

First approved in 1991

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H12N4O3
Molecular Weight	236.2273
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC[C@@H]1CC[C@@H](O1)N2C=NC3=C2N=CNC3=O

InChI

InChIKey=BXZVVICBKDXVGW-NKWVEPMBSA-N

InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020156s051lbl.pdf
Curator's Comment: description was created based on several sources, including https://www.ott.nih.gov/sites/default/files/documents/pdfs/VidexCS.pdf

Didanosine was developed by Bristol-Myers Squibb in collaboration with the NIH for the treatment of HIV-1 infections. Upon administration the drug is metabolized to the active metabolite which inhibits HIV-1 reverse transcriptase both by competing with deoxyadenosine 5'-triphosphate and by its incorporation into viral DNA. Didanosine was approved by FDA under the name Videx (among the other names).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus type 1 reverse transcriptase 67 Target ID: CHEMBL247 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020156s051lbl.pdf	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 151 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020156s051lbl.pdf	Primary		Approved 8429	VIDEX Approved Use Videx (didanosine, USP) is a nucleoside reverse transcriptase inhibitor for use in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV)-1 infection. Launch Date 1991

C_max

Value	Dose	Analyte	Population
6041 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	33 mg/kg bw 2 times / day steady-state, oral dose: 33 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
18019 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	16.5 mg/kg bw 2 times / day steady-state, intravenous dose: 16.5 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2257 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	6 mg/kg bw 2 times / day steady-state, oral dose: 6 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3041 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	3 mg/kg bw 2 times / day steady-state, intravenous dose: 3 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
291 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.4 mg/kg bw 2 times / day steady-state, intravenous dose: 0.4 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
343 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.8 mg/kg bw 2 times / day steady-state, oral dose: 0.8 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
5787 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	33 mg/kg bw single, oral dose: 33 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1494 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	6 mg/kg bw single, oral dose: 6 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
17974 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	16.5 mg/kg bw single, intravenous dose: 16.5 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
244 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.8 mg/kg bw single, oral dose: 0.8 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2818 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	3 mg/kg bw single, intravenous dose: 3 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
305 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.4 mg/kg bw single, intravenous dose: 0.4 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
14179 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	33 mg/kg bw 2 times / day steady-state, oral dose: 33 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
32264 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	16.5 mg/kg bw 2 times / day steady-state, intravenous dose: 16.5 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3377 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	6 mg/kg bw 2 times / day steady-state, oral dose: 6 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4118 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	3 mg/kg bw 2 times / day steady-state, intravenous dose: 3 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
418 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.4 mg/kg bw 2 times / day steady-state, intravenous dose: 0.4 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
421 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.8 mg/kg bw 2 times / day steady-state, oral dose: 0.8 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
12730 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	33 mg/kg bw single, oral dose: 33 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2374 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	6 mg/kg bw single, oral dose: 6 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
28257 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	16.5 mg/kg bw single, intravenous dose: 16.5 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
351 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.8 mg/kg bw single, oral dose: 0.8 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3726 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	3 mg/kg bw single, intravenous dose: 3 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
413 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.4 mg/kg bw single, intravenous dose: 0.4 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
1.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	33 mg/kg bw 2 times / day steady-state, oral dose: 33 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.49 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	16.5 mg/kg bw 2 times / day steady-state, intravenous dose: 16.5 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	6 mg/kg bw 2 times / day steady-state, oral dose: 6 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	3 mg/kg bw 2 times / day steady-state, intravenous dose: 3 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.93 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.4 mg/kg bw 2 times / day steady-state, intravenous dose: 0.4 mg/kg bw route of administration: Intravenous experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.8 mg/kg bw 2 times / day steady-state, oral dose: 0.8 mg/kg bw route of administration: Oral experiment type: STEADY-STATE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.64 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	33 mg/kg bw single, oral dose: 33 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.12 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	6 mg/kg bw single, oral dose: 6 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	16.5 mg/kg bw single, intravenous dose: 16.5 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.76 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.8 mg/kg bw single, oral dose: 0.8 mg/kg bw route of administration: Oral experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	3 mg/kg bw single, intravenous dose: 3 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.88 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1903100/	0.4 mg/kg bw single, intravenous dose: 0.4 mg/kg bw route of administration: Intravenous experiment type: SINGLE co-administered:	DIDANOSINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
25 mg/kg 1 times / day steady, oral Highest studied dose Dose: 25 mg/kg, 1 times / day Route: oral Route: steady Dose: 25 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/	unhealthy, 0.7 - 18.9 years n = 28 Health Status: unhealthy Condition: acquired immune deficiency syndrome Age Group: 0.7 - 18.9 years Sex: M+F Population Size: 28 Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/	DLT: Neuropathy, Pancreatitis... Dose limiting toxicities: Neuropathy (13 patients) Pancreatitis (6 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/
12.8 mg/kg 1 times / day steady, oral Recommended Dose: 12.8 mg/kg, 1 times / day Route: oral Route: steady Dose: 12.8 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/	unhealthy, 0.7 - 18.9 years n = 73 Health Status: unhealthy Condition: acquired immune deficiency syndrome Age Group: 0.7 - 18.9 years Sex: M+F Population Size: 73 Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/	DLT: Neuropathy, Pancreatitis... Dose limiting toxicities: Neuropathy (5 patients) Pancreatitis (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/
13 mg/kg 1 times / day steady, oral Recommended Dose: 13 mg/kg, 1 times / day Route: oral Route: steady Dose: 13 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/	unhealthy, 0.7 - 18.9 years n = 10000 Health Status: unhealthy Condition: acquired immune deficiency syndrome Age Group: 0.7 - 18.9 years Sex: M+F Population Size: 10000 Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/	DLT: Pancreatitis... Dose limiting toxicities: Pancreatitis (grade 5, 0.35%) Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/
20.5 mg/kg 1 times / day steady, oral (mean) Recommended Dose: 20.5 mg/kg, 1 times / day Route: oral Route: steady Dose: 20.5 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/	unhealthy, 0.7 - 18.9 years n = 32 Health Status: unhealthy Condition: acquired immune deficiency syndrome Age Group: 0.7 - 18.9 years Sex: M+F Population Size: 32 Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/	DLT: Neuropathy, Pancreatitis... Dose limiting toxicities: Neuropathy (8 patients) Pancreatitis (10 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/1379914/
500 mg 1 times / day steady, oral (median) Recommended Dose: 500 mg, 1 times / day Route: oral Route: steady Dose: 500 mg, 1 times / day Co-administed with:: ganciclovir(10 mg/kg) Sources: https://pubmed.ncbi.nlm.nih.gov/8381032/	unhealthy, adult n = 32 Health Status: unhealthy Condition: acquired immune deficiency syndrome Age Group: adult Sex: unknown Population Size: 32 Sources: https://pubmed.ncbi.nlm.nih.gov/8381032/	DLT: Neutropenia, Neutropenia... Disc. AE: Anemia, Thrombocytopenia... Dose limiting toxicities: Neutropenia (grade 4, 3 patients) Neutropenia (grade 3, 9 patients) Neuropathy (5 patients) Diarrhea (3 patients) Pancreatitis (2 patients) Serum alkaline phosphatase elevated (2 patients) Abdominal pain (1 patient) AEs leading to discontinuation/dose reduction: Anemia (grade 3, 4 patients) Thrombocytopenia (grade 3, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/8381032/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
BCRP 699	BCRP 561

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
BCRP 773	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/17202245/	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
BCRP 561	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/15345326/	likely

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:490877	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:490877
ChemicalBook	CB0680765	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0680765
MolPort	MolPort-002-507-371	https://www.molport.com/shop/molecule-link/MolPort-002-507-371
MolPort	MolPort-003-846-628	https://www.molport.com/shop/molecule-link/MolPort-003-846-628
MolPort	MolPort-006-167-656	https://www.molport.com/shop/molecule-link/MolPort-006-167-656
Selleck Chemicals	Didanosine(Videx)	http://www.selleckchem.com/products/Didanosine(Videx).html
ZINC	ZINC000013597823	http://zinc15.docking.org/substances/ZINC000013597823
eMolecules	1986517	https://www.emolecules.com/cgi-bin/more?vid=1986517
eMolecules	2724662	https://www.emolecules.com/cgi-bin/more?vid=2724662
eMolecules	30075948	https://www.emolecules.com/cgi-bin/more?vid=30075948
eMolecules	901757	https://www.emolecules.com/cgi-bin/more?vid=901757

PubMed

Title	Date	PubMed
Clinical and laboratory signs of mitochondrial dysfunction secondary to nucleoside analogue antiretroviral therapy are reversible.	2001	11515773
HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment.	2001	11506064
Delavirdine: clinical pharmacokinetics and drug interactions.	2001	11327199
[A rare etiology of hepatic steatosis associated with lactic acidosis: the toxicity of antiviral nucleoside analogues].	2001 Apr	11373588
Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1.	2001 Apr	11319914
Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.	2001 Apr	11312622
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.	2001 Apr	11306154
Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine.	2001 Apr 13	11371696
Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.	2001 Apr 13	11355843
High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.	2001 Apr 15	11391173
A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.	2001 Apr 15	11391161
[Didanosine as a capsule. A reliable drug in a new dosage form].	2001 Apr 2	11373794
Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes.	2001 Apr-Jun	11463208
Antiviral drugs: current state of the art.	2001 Aug	11418355
Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.	2001 Aug 15	11471110
Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.	2001 Feb 1	11462972
Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases.	2001 Jan-Feb	11488127
New developments in anti-HIV chemotherapy.	2001 Jan-Feb	11347962
Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.	2001 Jul	11450788
Gynaecomastia in a male patient during stavudine and didanosine treatment for HIV infection.	2001 Jul	11394987
A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.	2001 Jul 1	11464145
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.	2001 Jul 27	11504959
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.	2001 Jul 6	11426071
[Immunologic response to antiretroviral treatment with combined stavudine, didanosine and nevirapine].	2001 Jul 7-13	11505831
Nucleoside analogue-induced fatal lactic acidosis in two HIV-infected patients in Singapore.	2001 Jun	11547960
Full recovery from severe dilated cardiomyopathy in an HIV-infected patient.	2001 Jun	11449927
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.	2001 Jun 1	11404532
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.	2001 Jun 15	11416710
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).	2001 Jun 15	11372025
Mitochondrial toxic effects and ribavirin.	2001 Jun 2	11407389
Mitochondrial toxic effects and ribavirin.	2001 Jun 2	11407388
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.	2001 Jun 29	11442229
[Symptomatic hyperlactemia in patients infected with the human immunodeficiency virus treated with nucleoside analogs].	2001 Jun 9	11440700
Differential susceptibility of retroviruses to nucleoside analogues.	2001 Mar	11527046
Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.	2001 Mar	11417760
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.	2001 Mar 30	11316999
Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.	2001 Mar 30	11316991
Myelopathy in a previously asymptomatic HIV-1-infected patient.	2001 Mar-Apr	11339484
[HIV-HBV coinfection and the liver].	2001 May	11521107
Choosing which nuke to use first.	2001 May	11392690
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health.	2001 May 4	11399956
Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.	2001 May 5	11356442
Warning for pregnant women on HIV therapy.	2001 May-Jun	11458554
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.	2001 Sep	11448730
Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine.	2001 Sep 1	11559430
Liver failure after long-term nucleoside antiretroviral therapy.	2001 Sep 1	11556343
Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.	2001 Sep 14	11454872
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.	2001 Sep 15	11517441
Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients.	2001 Sep 7	11546950
Direct analysis of mitochondrial toxicity of antiretroviral drugs.	2001 Sep 7	11546944

Patents

Sample Use Guides

In Vivo Use Guide

In adult patients didanosine should be administered on an empty stomach at least 30 minutes before eating at the dose of 200 mg twice daily (body weight is at least 60 kg) or 125 mg twice daily (body weight is less than 60 kg). Pediatric patients (2 weeks old to 18 years old): the drug should be administered on an empty stomach at least 30 minutes before or 2 hours after eating at the dose of 100-120 mg per m2 twice daily.

Route of Administration: Oral

In Vitro Use Guide

The anti-HIV-1 activity of didanosine was evaluated in a variety of HIV-1 infected lymphoblastic cell lines and monocyte/macrophage cell cultures. The concentration of drug necessary to inhibit viral replication by 50% (EC50) ranged from 2.5 to 10 uM (1 uM = 0.24 ug/mL) in lymphoblastic cell lines and 0.01 to 0.1 uM in monocyte/macrophage cell cultures.

Name

Type

Language

DIDANOSINE

Official Name

English

DIDANOSINE [MI]

Common Name

English

(-)-DIDANOSINE

Common Name

English

didanosine [INN]

Common Name

English

DIDANOSINUM [WHO-IP LATIN]

Common Name

English

DIDANOSINE [USP IMPURITY]

Common Name

English

DIDANOSINE [EP MONOGRAPH]

Common Name

English

NSC-612049

Code

English

INOSINE, 2',3'-DIDEOXY-

Systematic Name

English

DIDEOXYINOSINE

Systematic Name

English

2',3'-DIDEOXYINOSINE

Systematic Name

English

DIDANOSINE [WHO-IP]

Common Name

English

DIDANOSINE [USAN]

Common Name

English

DIDANOSINE [VANDF]

Common Name

English

DIDANOSINE [ORANGE BOOK]

Common Name

English

DIDANOSINE SYSTEM SUITABILITY MIXTURE

Common Name

English

DIDANOSINE [USP-RS]

Common Name

English

DIDANOSINE [JAN]

Common Name

English

DIDANOSINE [EP IMPURITY]

Common Name

English

DIDANOSINE [MART.]

Common Name

English

BMY-40900

Code

English

DIDANOSINE SYSTEM SUITABILITY MIXTURE [USP-RS]

Common Name

English

DIDANOSINE [USP MONOGRAPH]

Common Name

English

DIDANOSINE [HSDB]

Common Name

English

Didanosine [WHO-DD]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000009947